Lexicon Ebt Per Ebit vs Current Ratio Analysis

LXRX Stock

USD 1.74 0.04 2.35%

Lexicon Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Lexicon Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexicon Pharmaceuticals is a good investment. Please check the relationship between Lexicon Pharmaceuticals Ebt Per Ebit and its Current Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Ebt Per Ebit vs Current Ratio

Ebt Per Ebit vs Current Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexicon Pharmaceuticals Ebt Per Ebit account and Current Ratio. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Lexicon Pharmaceuticals' Ebt Per Ebit and Current Ratio is 0.15. Overlapping area represents the amount of variation of Ebt Per Ebit that can explain the historical movement of Current Ratio in the same time period over historical financial statements of Lexicon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Lexicon Pharmaceuticals' Ebt Per Ebit and Current Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebt Per Ebit of Lexicon Pharmaceuticals are associated (or correlated) with its Current Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Ratio has no effect on the direction of Ebt Per Ebit i.e., Lexicon Pharmaceuticals' Ebt Per Ebit and Current Ratio go up and down completely randomly.

Correlation Coefficient

0.15

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ebt Per Ebit

Current Ratio

A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.

Most indicators from Lexicon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexicon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.At this time, Lexicon Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 145.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.59) in 2024.

	2023	2024 (projected)
Extraordinary Items	3.6M	3.2M
Reconciled Depreciation	510K	484.5K

Extraordinary Items Reconciled Depreciation

Lexicon Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Assets
Total Assets		0.41	0.36	0.68	0.39	0.36	0.51	-0.57	-0.11	0.47	0.84	0.74	0.13	0.98	0.18	-0.05	0.88	0.72	0.53	0.43	0.78	0.3	0.98	0.33	0.53	-0.39
Short Long Term Debt Total	0.41		0.57	0.46	-0.21	-0.12	0.25	0.37	-0.35	0.54	0.17	0.19	-0.18	0.38	0.57	0.15	0.51	0.89	0.1	-0.11	0.83	-0.17	0.44	0.07	0.24	-0.22
Other Current Liab	0.36	0.57		0.57	-0.24	-0.19	0.57	0.22	-0.23	0.39	0.08	-0.04	-0.15	0.38	0.72	0.2	0.64	0.53	0.03	-0.18	0.6	-0.22	0.45	-0.14	0.09	-0.06
Total Current Liabilities	0.68	0.46	0.57		0.31	-0.02	0.82	-0.37	-0.18	0.86	0.65	0.3	-0.13	0.74	0.16	0.05	0.8	0.58	0.12	0.35	0.8	-0.09	0.73	0.28	0.25	-0.29
Total Stockholder Equity	0.39	-0.21	-0.24	0.31		0.2	0.12	-0.55	0.31	0.18	0.48	0.24	-0.2	0.44	-0.35	-0.18	0.35	-0.02	0.38	0.78	0.1	0.12	0.4	0.45	-0.12	-0.25
Property Plant And Equipment Net	0.36	-0.12	-0.19	-0.02	0.2		-0.22	-0.39	0.41	0.02	0.35	0.77	-0.17	0.22	-0.03	-0.46	0.2	0.19	-0.15	0.14	0.13	0.98	0.19	0.14	0.13	-0.48
Current Deferred Revenue	0.51	0.25	0.57	0.82	0.12	-0.22		-0.29	-0.43	0.59	0.46	0.03	0.13	0.63	0.09	0.38	0.64	0.36	0.0	0.28	0.57	-0.22	0.61	-0.08	0.35	0.11
Net Debt	-0.57	0.37	0.22	-0.37	-0.55	-0.39	-0.29		-0.33	-0.17	-0.86	-0.49	-0.23	-0.6	0.48	0.43	-0.37	-0.02	-0.39	-0.38	-0.15	-0.35	-0.53	-0.34	-0.16	0.42
Retained Earnings	-0.11	-0.35	-0.23	-0.18	0.31	0.41	-0.43	-0.33		-0.26	0.14	0.0	-0.13	-0.12	-0.06	-0.89	-0.16	-0.22	-0.05	-0.22	-0.23	0.33	-0.13	0.34	-0.75	-0.6
Accounts Payable	0.47	0.54	0.39	0.86	0.18	0.02	0.59	-0.17	-0.26		0.49	0.31	-0.24	0.49	0.04	0.09	0.65	0.56	-0.01	0.29	0.73	-0.02	0.47	0.24	0.25	-0.18
Cash	0.84	0.17	0.08	0.65	0.48	0.35	0.46	-0.86	0.14	0.49		0.63	0.13	0.86	-0.21	-0.35	0.69	0.52	0.48	0.37	0.62	0.27	0.82	0.39	0.31	-0.55
Non Current Assets Total	0.74	0.19	-0.04	0.3	0.24	0.77	0.03	-0.49	0.0	0.31	0.63		-0.08	0.6	-0.06	-0.17	0.53	0.52	0.27	0.38	0.5	0.74	0.58	0.19	0.56	-0.39
Non Currrent Assets Other	0.13	-0.18	-0.15	-0.13	-0.2	-0.17	0.13	-0.23	-0.13	-0.24	0.13	-0.08		0.2	-0.1	0.1	-0.03	-0.11	0.21	-0.24	-0.13	-0.06	0.18	0.17	0.21	0.25
Cash And Short Term Investments	0.98	0.38	0.38	0.74	0.44	0.22	0.63	-0.6	-0.12	0.49	0.86	0.6	0.2		0.13	-0.01	0.89	0.67	0.54	0.45	0.77	0.16	0.99	0.33	0.47	-0.34
Net Receivables	0.18	0.57	0.72	0.16	-0.35	-0.03	0.09	0.48	-0.06	0.04	-0.21	-0.06	-0.1	0.13		-0.01	0.3	0.41	-0.06	-0.37	0.36	-0.08	0.23	0.13	0.04	-0.23
Common Stock Shares Outstanding	-0.05	0.15	0.2	0.05	-0.18	-0.46	0.38	0.43	-0.89	0.09	-0.35	-0.17	0.1	-0.01	-0.01		0.07	0.02	-0.03	0.3	0.03	-0.36	-0.01	-0.48	0.49	0.84
Short Term Investments	0.88	0.51	0.64	0.8	0.35	0.2	0.64	-0.37	-0.16	0.65	0.69	0.53	-0.03	0.89	0.3	0.07		0.71	0.41	0.39	0.82	0.16	0.9	0.18	0.38	-0.27
Non Current Liabilities Total	0.72	0.89	0.53	0.58	-0.02	0.19	0.36	-0.02	-0.22	0.56	0.52	0.52	-0.11	0.67	0.41	0.02	0.71		0.22	0.05	0.95	0.12	0.7	0.1	0.35	-0.37
Other Current Assets	0.53	0.1	0.03	0.12	0.38	-0.15	0.0	-0.39	-0.05	-0.01	0.48	0.27	0.21	0.54	-0.06	-0.03	0.41	0.22		0.41	0.21	-0.21	0.56	0.31	0.3	-0.16
Other Stockholder Equity	0.43	-0.11	-0.18	0.35	0.78	0.14	0.28	-0.38	-0.22	0.29	0.37	0.38	-0.24	0.45	-0.37	0.3	0.39	0.05	0.41		0.17	0.11	0.4	0.16	0.35	0.06
Total Liab	0.78	0.83	0.6	0.8	0.1	0.13	0.57	-0.15	-0.23	0.73	0.62	0.5	-0.13	0.77	0.36	0.03	0.82	0.95	0.21	0.17		0.06	0.79	0.17	0.35	-0.38
Property Plant And Equipment Gross	0.3	-0.17	-0.22	-0.09	0.12	0.98	-0.22	-0.35	0.33	-0.02	0.27	0.74	-0.06	0.16	-0.08	-0.36	0.16	0.12	-0.21	0.11	0.06		0.13	0.05	0.18	-0.33
Total Current Assets	0.98	0.44	0.45	0.73	0.4	0.19	0.61	-0.53	-0.13	0.47	0.82	0.58	0.18	0.99	0.23	-0.01	0.9	0.7	0.56	0.4	0.79	0.13		0.34	0.47	-0.35
Short Term Debt	0.33	0.07	-0.14	0.28	0.45	0.14	-0.08	-0.34	0.34	0.24	0.39	0.19	0.17	0.33	0.13	-0.48	0.18	0.1	0.31	0.16	0.17	0.05	0.34		-0.04	-0.52
Common Stock	0.53	0.24	0.09	0.25	-0.12	0.13	0.35	-0.16	-0.75	0.25	0.31	0.56	0.21	0.47	0.04	0.49	0.38	0.35	0.3	0.35	0.35	0.18	0.47	-0.04		0.16
Other Assets	-0.39	-0.22	-0.06	-0.29	-0.25	-0.48	0.11	0.42	-0.6	-0.18	-0.55	-0.39	0.25	-0.34	-0.23	0.84	-0.27	-0.37	-0.16	0.06	-0.38	-0.33	-0.35	-0.52	0.16

Click cells to compare fundamentals

Lexicon Pharmaceuticals Account Relationship Matchups

Lexicon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	417.7M	203.8M	136.9M	194.3M	229.4M	326.8M
Short Long Term Debt Total	246.3M	12.8M	2.3M	55.3M	106.1M	75.1M
Other Current Liab	42.2M	976K	11.9M	11.5M	15.9M	11.6M
Total Current Liabilities	65.3M	46.8M	22.1M	23.2M	31.5M	48.4M
Total Stockholder Equity	(1.3B)	156.4M	(1.5B)	(1.6B)	93.1M	97.8M
Property Plant And Equipment Net	14.0M	295K	1.2M	2.1M	7.5M	7.1M
Net Debt	210.2M	(113.5M)	(61.8M)	8.9M	83.6M	87.8M
Retained Earnings	(1.3B)	(1.4B)	(1.5B)	(1.6B)	(1.8B)	(1.7B)
Accounts Payable	12.2M	5.5M	9.2M	10.4M	14.4M	13.3M
Cash	36.1M	126.3M	64.1M	46.3M	22.5M	21.3M
Non Current Assets Total	80.0M	46.1M	48.0M	53.4M	52.9M	104.9M
Non Currrent Assets Other	1.7M	1.2M	2.3M	6.8M	828K	786.6K
Cash And Short Term Investments	271.7M	152.3M	86.7M	138.4M	170.0M	206.8M
Net Receivables	56.5M	395K	14K	28K	1.0M	959.5K
Common Stock Shares Outstanding	116.7M	110.8M	145.7M	165.7M	221.1M	232.2M
Short Term Investments	235.5M	26.0M	22.7M	92.0M	147.6M	137.0M
Liabilities And Stockholders Equity	(1.0B)	203.8M	(1.5B)	(1.5B)	229.4M	240.9M
Non Current Liabilities Total	235.3M	611K	1.2M	54.0M	104.8M	100.6M
Other Current Assets	5.3M	5.0M	2.2M	2.5M	5.1M	6.8M
Other Stockholder Equity	(190K)	1.6B	(140K)	239K	1.9B	2.0B
Total Liab	300.6M	47.4M	23.3M	77.2M	136.3M	149.0M
Property Plant And Equipment Gross	14.0M	295K	6.0M	12.9M	12.0M	11.4M
Total Current Assets	337.8M	157.7M	88.9M	140.9M	176.5M	221.8M
Accumulated Other Comprehensive Income	84K	(6K)	(10K)	(428K)	31K	32.6K
Short Term Debt	11.0M	12.2M	1.1M	1.3M	1.2M	1.1M
Other Assets	285K	(45K)	1.2M	136.9M	157.4M	165.3M
Long Term Debt	231.6M	243.9M	234.2M	48.6M	99.5M	77.2M
Property Plant Equipment	14.0M	295K	1.2M	2.1M	1.9M	1.8M
Other Liab	29.9M	55.4M	35.8M	23.3M	26.8M	43.1M
Treasury Stock	(3.8M)	(4.8M)	(7.5M)	(2.1M)	(1.9M)	(1.9M)
Net Tangible Assets	52.8M	111.8M	69.1M	72.6M	65.3M	67.6M
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.5B)	(1.6B)	(1.4B)	(1.5B)
Capital Surpluse	1.5B	1.6B	1.6B	1.7B	2.0B	1.5B
Inventory	1.9M	4.7M	4.2M	1.0	381K	362.0K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lexicon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexicon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexicon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexicon Pharmaceuticals Stock:

How To Invest In Lexicon

Details

Is Lexicon Stock a good investment?

Details

What is Lexicon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Complementary Tools for Lexicon Stock analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Global Correlations Find global opportunities by holding instruments from different markets
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Transaction History View history of all your transactions and understand their impact on performance
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.63)

Earnings Share

(0.80)

Revenue Per Share

0.005

Quarterly Revenue Growth

24.071

Return On Assets

(0.51)

The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lexicon Ebt Per Ebit vs Current Ratio Analysis

Ebt Per Ebit vs Current Ratio

Ebt Per Ebit vs Current Ratio Correlation Analysis

Correlation Coefficient

Ebt Per Ebit

Current Ratio

Lexicon Pharmaceuticals fundamental ratios Correlations

Lexicon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lexicon Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Lexicon Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.95	Non Current Liabilities Total
Total Current Assets	+ 0.9	Short Term Investments

Common Stock Shares Outstanding	- 0.89	Retained Earnings
Cash	- 0.86	Net Debt
Common Stock	- 0.75	Retained Earnings
Other Assets	- 0.6	Retained Earnings
Cash And Short Term Investments	- 0.6	Net Debt
Net Debt	- 0.57	Total Assets